KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) EBITDA Margin (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBITDA Margin for 17 consecutive years, with 17.15% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 2589.0% to 17.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.83%, a 865.0% decrease, with the full-year FY2025 number at 1.83%, down 865.0% from a year prior.
  • EBITDA Margin was 17.15% for Q4 2025 at Bio-Rad Laboratories, down from 10.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.99% in Q3 2021 to a low of 17.15% in Q4 2025.
  • A 5-year average of 11.96% and a median of 13.89% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 779bps in 2021, then plummeted -2589bps in 2025.
  • Bio-Rad Laboratories' EBITDA Margin stood at 16.09% in 2021, then rose by 7bps to 17.28% in 2022, then decreased by -19bps to 13.99% in 2023, then tumbled by -38bps to 8.74% in 2024, then plummeted by -296bps to 17.15% in 2025.
  • Per Business Quant, the three most recent readings for BIO's EBITDA Margin are 17.15% (Q4 2025), 10.0% (Q3 2025), and 11.83% (Q2 2025).